An ounce of prevention The new wave in HIV therapy

I N THE EARLY YEARS OF THE ACQUIRED IMMUNE DEFICIENCY
syndrome (AIDS) era, patient m an agem ent consisted of treating human immunodeficiency virus (HIV) -associated complications . Although this remains an important part of AIDS care. there has been an emerging trend towards secondary and primary prevention of major HN-associated complications. Preliminary studies have suggested prophylactic therapy to be beneficial for Pneumocystis carinii pneumonia (PCP), tubercu losis, Mycobacterium avium complex (MAC) infection, toxoplasmosis. cryptococcosis and cytom egalovirus (CMV) retinitis.
PNEUMOCYSTIS CARINI/ PNEU MONIA
On June 16. 1989, the Centers for Disease Control (CDC) published guidelines for secondary prophylaxis for patients with previous PCP and primary prophylaxis for patients with a CD4lymphocyte count less than 200 x 10 6 /L or those whose CD4 cells rep resent less than 20% of the total lymphocyte population (1). The CDC gu idelines recommend eith er trimethoprim-s ulfamethoxazole (TMP-SMZ) or aerosolized penlamidine (AP). However. a recent trial comparing TMP-SMZ, one double stren gth tablet daily. to AP. 3 00 mg every four weeks via Respirgard II jet nebulizer (Ma rquest. Englewood, CO) AIDS Clinical Trial Gro up (ACTG021), was stopped by the data and safety monitoring board. Twenty-U1ree centres enrolled 3 10 58 patients with previous PCP with a mean CD4 count of 56 x 10 6 /L. The trial was terminated after 50 PCP recurren ces: 14 on TMP-SMZ and 36 on AP. The projected failure rate at 12 months was 4 .5% fo r TMP-SMZ and 18 .5% for AP.
This study suggests that TMP-SMZ, which is much less expensive than AP, should be the initial PCP regimen of choice for secondary prophylaxis. The regimen of choice in patients intolerant of TMP-SMZ is less clear. While AP is effective, it may be argued thal dapsone with or without TMP is preferred because boU1 a re less expensive than AP and since TMP plus dapsone is as effective as TMP-SMZ in treating PCP (2) .
MYCOBAC TERIUM TUBERCULOSIS
Isoniazid preventive therapy is recommended for tuberculin-positive HN-infected patients (defined as more than 5 mm induration) (3).
MYCOBACTERIUM AV/UM C OMPLEX
Recently, a trial comparing rifabutin 300 m g/day vers u s placebo for primary prevention of MAC bacteremia in AIDS patients with a CD4 lymphocyte count below 200 x 10 6 /L was stopped by the data and safety monitoring board, since rifabutin s ignificantly reduced the incidence of MAC bacteremia. A sin1ilar trial in San Francisco using clofazimine alone showed no efficacy (unpublished data) . A trial evaluating clarithromycin for the prevention of MAC bacteremia is about to start in the United States (ACTG196).
TOXOPLASMOSIS
Cerebral toxoplasmosis occurs in approximately 30% of toxoplasma-seropositive. HIV-infected individuals. Secondary prophylaxis is an accepted part of management (4). Althou gh a clinical trial of primary prophylaxis in such patients has not been performed. decision analysis has concluded that such therapy probably saves lives (5). It is possible that PCP prophylaxis regimens containing TMP with SMZ or dapsone will prevent toxoplasmosis.
CRYPTOCOCCOSIS
Cryptococcosis occurs in 5 to 10% of AIDS patients (6). It is currently not possible to identify patients at risk for this infection and although fluconazole is effective for secondary prophylaxis of cryptococcosis (7), primary prophylaxis cannot be recommended at present. However, the probable efficacy of fluconazole in primary prevention of cryptococcosis is one of several reasons for preferring fluconazole to ketoconazole when oral azole therapy is required for candidiasis.
CYTOM EGALOVIRUS DISEASE
Symptomatic CMV disease occurs in up to 20% of AIDS patients. with retinitis being more common than gas train tes tinal disease. Secondary prophylaxis of CMV retinitis is standard practice (8) . There presently is no evidence supporting the use of primary prophylaxis to prevent CMV disease. However. there is one study in bone marrow transplantation (9) and a second in renal transplantation (10) indicating some efficacy for high dose oral acyclovir in preventing CMV disease. Oral acyclovir is not an ideal therapy for CMV infection because of its poor activity against CMV and its poor oral bioavailability.
Within the next five years there likely will be an orally absorbed agent with reasonable anti-CMV activity and. primary prevention of CMV disease in HIV-infected patients will be achieved.
LYMPHOMA
As AIDS patients live longer. the incidence of AIDS-associated lymphoma has increased (11) . Most of U1ese lymphomas contain Epstein-Barr virus (EBV) genomic material (12) . It is conceivable that an anti-EBV drug would decrease the incidence of HIV-associated lymphoma. If effective orally administered anti-CMV drugs are developed and if the same drugs have significant anti -EBV activity as well, they may reduce the incidence of HIV-associated lymphoma.
Adult infectious disease notes
SUMMARY
We have entered an era of prevention of HIV-associated opportunistic in fections . Primary p revention cur rently is recommended fo r PCP and tubercu losis. Secondary prevention is standard fo r cryptococcosis. toxoplasm osis and CMV retinitis. Recently, primary prevention of MAC bacteremia has been achieved. It is li kely tl1at primary prevention of toxoplasm osis is effective. It is speculated tl1at orally absorbed drugs with reasonab le activity against CMV and EBV will be available and offer primary prevention of disease due to these viruses.
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